Skip to content

Study · Case report or series · n = 1 · 2026

9 results

Sequential Liraglutide and Setmelanotide Therapy in Bardet-Biedl Syndrome: Metabolic and Renal Outcomes in a Real-World Case Report and Literature Review.

Pasquariello T, Secondulfo F, Roscini AR, Nardi E, Prosperi E, Capasso G, Perna A, Zacchia M

Nephron15 Sept 2026

PMID42743093 (opens in a new tab)DOI10.1159/nef/adtag006 (opens in a new tab)PepBankPUB-42743093
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one 37-year-old man with BBS10-associated Bardet-Biedl syndrome and obesity, the liraglutide phase showed -3.4% weight change within 8 months.

    In plain wordsIn one man with BBS10-associated Bardet-Biedl syndrome and obesity, liraglutide was followed by 3.4% weight loss within 8 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −3.4%
    liraglutide phase;within 8 months

    Source sentences

    Summary
    Treatment with liraglutide induced modest weight loss (-3.4%, BMI 35.2→34 kg/m2) and improved urinary albumin-to-creatinine ratio (uACR) and liver enzymes levels within 8 months.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  2. 02HumanCase report or seriesEfficacy outcome

    In one 37-year-old man with BBS10-associated Bardet-Biedl syndrome and obesity, BMI fell from 35.2 to 34 kg/m² during the liraglutide phase within 8 months.

    In plain wordsIn one man with BBS10-associated Bardet-Biedl syndrome and obesity, BMI fell from 35.2 to 34 during the liraglutide phase.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI
    35.2 kg/m²
    before liraglutide
    BMI
    34 kg/m²
    liraglutide phase;within 8 months

    Source sentences

    Summary
    Treatment with liraglutide induced modest weight loss (-3.4%, BMI 35.2→34 kg/m2) and improved urinary albumin-to-creatinine ratio (uACR) and liver enzymes levels within 8 months.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  3. 03HumanCase report or seriesEfficacy outcome

    In one man with BBS10-associated Bardet-Biedl syndrome and obesity, urinary albumin-to-creatinine ratio improved during the liraglutide phase within 8 months; signed change was unstated.

    In plain wordsIn one man with BBS10-associated Bardet-Biedl syndrome and obesity, a urine kidney marker improved during the liraglutide phase.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedUrinary albumin-to-creatinine ratio
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with liraglutide induced modest weight loss (-3.4%, BMI 35.2→34 kg/m2) and improved urinary albumin-to-creatinine ratio (uACR) and liver enzymes levels within 8 months.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  4. 04HumanCase report or seriesEfficacy outcome

    In one man with BBS10-associated Bardet-Biedl syndrome and obesity, liver enzyme levels improved during the liraglutide phase within 8 months; signed change was unstated.

    In plain wordsIn one man with BBS10-associated Bardet-Biedl syndrome and obesity, liver enzyme levels improved during the liraglutide phase.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedLiver enzyme levels
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with liraglutide induced modest weight loss (-3.4%, BMI 35.2→34 kg/m2) and improved urinary albumin-to-creatinine ratio (uACR) and liver enzymes levels within 8 months.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  5. 05HumanCase report or seriesEfficacy outcome

    In a man with BBS, liver transaminases normalized after 12 months of setmelanotide following liraglutide discontinuation.

    In plain wordsIn a man with BBS, liver enzyme levels became normal during setmelanotide treatment after liraglutide stopped.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedLiver transaminase normalization
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment, the patient achieved a 10.5% weight loss compared with baseline (BMI 35.2→31.5 kg/m2), normalization of liver transaminases, reduced liver stiffness, and sustained improvement in uACR, while eGFR remained stable.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  6. 06HumanCase report or seriesEfficacy outcome

    In a man with BBS, liver stiffness decreased after 12 months of setmelanotide following liraglutide discontinuation.

    In plain wordsIn a man with BBS, liver stiffness decreased during setmelanotide treatment after liraglutide stopped.

    Peptide
    Setmelanotide
    Outcome
    DecreaseLiver stiffness
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment, the patient achieved a 10.5% weight loss compared with baseline (BMI 35.2→31.5 kg/m2), normalization of liver transaminases, reduced liver stiffness, and sustained improvement in uACR, while eGFR remained stable.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  7. 07HumanCase report or seriesEfficacy outcome

    In a man with BBS, eGFR remained stable after 12 months of setmelanotide following liraglutide discontinuation.

    In plain wordsIn a man with BBS, estimated kidney filtration remained stable during setmelanotide treatment after liraglutide stopped.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedEstimated glomerular filtration rate stability
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment, the patient achieved a 10.5% weight loss compared with baseline (BMI 35.2→31.5 kg/m2), normalization of liver transaminases, reduced liver stiffness, and sustained improvement in uACR, while eGFR remained stable.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  8. 08HumanCase report or seriesEfficacy outcome

    In a man with BBS, fasting insulin improved during setmelanotide treatment after liraglutide discontinuation.

    In plain wordsIn a man with BBS, fasting insulin improved during setmelanotide treatment after liraglutide stopped.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedFasting insulin
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Fasting insulin and HOMA-IR improved.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.
  9. 09HumanCase report or seriesEfficacy outcome

    In a man with BBS, HOMA-IR improved during setmelanotide treatment after liraglutide discontinuation.

    In plain wordsIn a man with BBS, the HOMA-IR measure of insulin resistance improved during setmelanotide treatment after liraglutide stopped.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedHOMA-IR
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Fasting insulin and HOMA-IR improved.
    2 context sentences
    Summary · context
    We report the case of a 37-year-old male with genetically confirmed BBS due to compound heterozygous likely pathogenic BBS10 variants presenting with obesity, insulin resistance, dyslipidemia, albuminuria, and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Following discontinuation of liraglutide, setmelanotide therapy was subsequently initiated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 5Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 2 times, first on 28 Oct 2026, 02:03 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.